CMPX Stock Forecast 2025-2026
Distance to CMPX Price Targets
CMPX Price Momentum
🤔 Considering Compass Therapeutics (CMPX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest CMPX Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, CMPX has a bullish consensus with a median price target of $10.00 (ranging from $4.00 to $32.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $2.46, the median forecast implies a 306.5% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,200.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMPX Analyst Ratings
CMPX Price Target Range
Latest CMPX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMPX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $32.00 |
| Feb 25, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $32.00 |
| Feb 24, 2025 | Guggenheim | Michael Schmidt | Buy | Initiates | $12.00 |
| Feb 19, 2025 | Piper Sandler | Biren Amin | Overweight | Initiates | $12.00 |
| Feb 10, 2025 | Jefferies | Maury Raycroft | Buy | Maintains | $8.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Jan 8, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $32.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $10.00 |
| Dec 23, 2024 | D. Boral Capital | Buy | Initiates | $0.00 | |
| Nov 15, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Sep 16, 2024 | Ladenburg Thalmann | Aydin Huseynov | Buy | Upgrade | $5.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Aug 7, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $8.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| May 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| May 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Apr 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
Compass Therapeutics Inc. (CMPX) Competitors
The following stocks are similar to Compass Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Compass Therapeutics Inc. (CMPX) Financial Data
Compass Therapeutics Inc. has a market capitalization of $340.17M with a P/E ratio of 0.0x. The company generates $850,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -6,661.8% and return on equity of -36.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Compass Therapeutics Inc. (CMPX) Business Model
About Compass Therapeutics Inc.
Develops immune-based therapies for cancer treatment.
Compass Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of next-generation monoclonal antibodies combined with other therapies. The company generates revenue through partnerships, licensing agreements, and eventually by bringing successful drug candidates to market following clinical trials.
The firm is positioned within the biotechnology sector, targeting significant medical challenges in oncology. Its proprietary scientific platform underpins its research efforts, with the potential to transform cancer treatment and improve patient outcomes, making it an attractive investment in the emerging biotech space.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
35
CEO
Dr. Thomas J. Schuetz M.D., Ph.D.
Country
United States
IPO Year
2021
Website
www.compasstherapeutics.comCompass Therapeutics Inc. (CMPX) Latest News & Analysis
Top-line Phase 2/3 results for tovecimig (CTX-009) in biliary tract cancer are expected by Q1 2025, alongside a new Investigator Sponsored Study for first-line treatment starting in the same period.
The upcoming data readout for tovecimig in biliary tract cancer could impact its market potential and investor sentiment, influencing stock performance in biotechnology focused on cancer therapies.
Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects.
Growing optimism and a Zacks Rank upgrade to #2 suggest potential for increased stock value and positive earnings outlook, influencing investment decisions in Compass Therapeutics.
Momentum investing involves buying rising stocks and selling them before they drop, focusing on short-term gains over long-term strategies.
Momentum investing offers a strategy for short-term gains by capitalizing on rising stock trends, impacting trading strategies and market volatility.
CMPX stock has more than doubled due to positive updates on pipeline development programs and the company's current cash position.
CMPX's stock surge indicates strong investor confidence in its pipeline prospects and financial stability, potentially signaling future growth and profitability.
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
3 months agoCompass Therapeutics appointed Barry Shin as Chief Financial Officer, effective December 9, 2024. Shin brings over 20 years of experience in biopharmaceutical finance and operations.
The appointment of an experienced CFO like Barry Shin can enhance financial management and strategic direction, potentially increasing investor confidence and impacting stock performance.
Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have shown performance metrics relative to their sector in the current year. Specific performance details were not provided.
The performance comparison indicates competitive positioning and market sentiment for CMPX and BMY, influencing investment decisions and potential stock valuations in their sector.
Frequently Asked Questions About CMPX Stock
What is Compass Therapeutics Inc.'s (CMPX) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Compass Therapeutics Inc. (CMPX) has a median price target of $10.00. The highest price target is $32.00 and the lowest is $4.00.
Is CMPX stock a good investment in 2025?
According to current analyst ratings, CMPX has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CMPX stock?
Wall Street analysts predict CMPX stock could reach $10.00 in the next 12 months. This represents a 306.5% increase from the current price of $2.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Compass Therapeutics Inc.'s business model?
Compass Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of next-generation monoclonal antibodies combined with other therapies. The company generates revenue through partnerships, licensing agreements, and eventually by bringing successful drug candidates to market following clinical trials.
What is the highest forecasted price for CMPX Compass Therapeutics Inc.?
The highest price target for CMPX is $32.00 from Jason Kolbert at D. Boral Capital, which represents a 1,200.8% increase from the current price of $2.46.
What is the lowest forecasted price for CMPX Compass Therapeutics Inc.?
The lowest price target for CMPX is $4.00 from at , which represents a 62.6% increase from the current price of $2.46.
What is the overall CMPX consensus from analysts for Compass Therapeutics Inc.?
The overall analyst consensus for CMPX is bullish. Out of 12 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are CMPX stock price projections?
Stock price projections, including those for Compass Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
